# Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC

Source: https://onco.cc/trials/nct06817525/  
OnCo record `nct06817525` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Henan Cancer Hospital, now recruiting.

## Summary

Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC is a phase 2, randomised interventional study registered as NCT06817525 by Henan Cancer Hospital, with a registry enrolment figure of 64 participants, started 2024-11-06 and due to reach its primary completion in 2026-05-31. Interventions recorded: 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1); 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1). Conditions listed: Triple-negative Breast Cancer. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06817525
- Phase: 2
- Setting: Nab-P+Cb+PD1 Inhibitor Neoadjuvant Therapy for Early TNBC: a Single Center, Non Blinded, Randomized Phase II Clinical Trial
- Sponsor: Henan Cancer Hospital
- Enrolled: 64

## Sources

- ClinicalTrials.gov NCT06817525: https://clinicaltrials.gov/study/NCT06817525

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06817525.json